The funds described herein are open to “accredited investors” only, through an offering made in accordance with Regulation D, Rule 506(c) of the Securities Act of 1933, as amended. In purchasing securities through a 506(c) offering, we are obligated to verify any participating investor’s status as an “accredited investor” in accordance with Rule 501 of Regulation D. Investors should consider the investment objectives, risks, charges, and expenses of the fund carefully before investing. We do not make any representations as to the accuracy or completeness of the information contained on this website and undertake no obligation to update the information. Past performance is not an indicator of any future results. All investments contain risk and may lose value. This does not constitute an offer to sell or a solicitation of interest to purchase any securities or investment advisory services in any country or jurisdiction in which such offer or solicitation is not permitted by law.

Why We Are Different- Dr. David Karli

Public demand for emerging biomedical technologies is higher than ever. Patients, investors and philanthropic supporters find themselves in unfamiliar territory, now as consumers of cutting-edge medical options which require diligence and careful consideration. There are little direction and sound resources for the patient consumer to understand the what, where and who(?) regarding investments of time, money and risk in fields like regenerative medicine and stem cell therapies, age management medicine, nutrition and supplementation and genetic testing. The piece will introduce Dr. David Karli, who has had unique and intensive exposure to these emerging medical and scientific fields. Is tomorrow’s medicine here today? Is modern med-tech hope or hype?

(Visited 41 times, 1 visits today)